Short Interest in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Declines By 62.7%

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 15,500 shares, a decline of 62.7% from the January 31st total of 41,500 shares. Based on an average daily trading volume, of 143,200 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.0% of the shares of the stock are short sold.

Institutional Trading of Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC acquired a new position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned 1.08% of Sonoma Pharmaceuticals as of its most recent SEC filing. 1.95% of the stock is owned by hedge funds and other institutional investors.

Sonoma Pharmaceuticals Stock Down 7.2 %

Shares of NASDAQ:SNOA opened at $2.20 on Friday. The company has a market capitalization of $3.56 million, a P/E ratio of -0.55 and a beta of 1.43. The stock’s fifty day simple moving average is $2.61 and its 200-day simple moving average is $2.59. Sonoma Pharmaceuticals has a 52-week low of $2.20 and a 52-week high of $9.37.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its quarterly earnings results on Wednesday, February 5th. The company reported ($0.59) earnings per share for the quarter. Sonoma Pharmaceuticals had a negative net margin of 26.82% and a negative return on equity of 68.98%. On average, sell-side analysts anticipate that Sonoma Pharmaceuticals will post -0.67 earnings per share for the current year.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.